CHTR vs IBRX · P/E 11, rev $55.09B vs rev $113.3M
Charter Communications Inc (CHTR) versus Immunitybio Inc (IBRX) — a side-by-side from cached financials, not a winner call.
Charter Communications Inc (CHTR) is a telecom services company listed on US.
Immunitybio Inc (IBRX) is a biotechnology company listed on US.
Latest reported CHTR revenue for 2024-12-31 was $55.09B. Net income was $5.85B. Revenue was up 0.9% from 2023-12-31 to 2024-12-31. CHTR currently screens at market cap $56.24B and trailing P/E 11.5.
Latest reported IBRX revenue for 2025-12-31 was $113.3M. Net income was -$351.4M. Revenue was up 668.3% from 2024-12-31 to 2025-12-31. IBRX currently screens at market cap $7.88B.
CHTR currently screens at market cap $56.24B and trailing P/E 11.5. IBRX currently screens at market cap $7.88B.
Not investment advice. Open the CHTR and IBRX stock pages for the full models.
Not investment advice.